BB
BB Biotech Portfolio holdings
AUM
$3.98B
1-Year Est. Return
15.06%
1 Year Est. Return
+15.06%
AUM
$3.98B
AUM Growth
+$856M
(+27%)
Holding
36
Top Buys
| 1 | +$28.9M | |
| 2 | +$23.4M | |
| 3 | +$21.5M | |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$20.2M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$13.6M |
Top Sells
| 1 | +$82.5M | |
| 2 | +$25.5M | |
| 3 | +$16.2M | |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$13M |
| 5 |
Gilead Sciences
GILD
|
+$12.4M |
Sector Composition
| 1 | Healthcare | 96.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALDR
26
DELISTED
Alder Biopharmaceuticals
ALDR
| $37.8M | 0.95% |
2,766,008
|
|
||
27
CRISPR Therapeutics
CRSP
$5.03B
| $28.9M | 0.73% |
+810,462
|
|
||
28
Scholar Rock
SRRK
$4.25B
| $27.8M | 0.7% |
1,476,839
+196,861
|
|
||
|
ITCI
29
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $26.8M | 0.67% |
2,200,000
|
|
||
30
Sangamo Therapeutics
SGMO
$146M
| $25.3M | 0.64% |
2,650,000
+1,300,000
|
|
||
31
Kezar Life Sciences
KZR
$45M
| $21.7M | 0.54% |
122,050
+40,207
|
|
||
|
GTHX
32
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $11.2M | 0.28% |
671,925
|
|
||
33
Cidara Therapeutics
CDTX
$6.91B
| $6.08M | 0.15% |
114,764
|
|
||
34
Novavax
NVAX
$1.09B
| $4.59M | 0.12% |
416,500
|
|
||
35
Q32 Bio
QTTB
$41.7M
| $2.53M | 0.06% |
+5,074
|
|
||
36
Regeneron Pharmaceuticals
REGN
$77.8B
| – | – |
-68,156
|
|